AYTU BIOPHARMA, INC
Close on Oct 19, 2026
- Market cap
- $37.82M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2026 Ended Jun 30, 2026 | Sep 22, 2026 | During market hours | $16.10M | $0.00 | – |
| Q3 FY2026 Ended Mar 31, 2026 | May 13, 2026 | During market hours | $12.40M | $-0.53 | – |
| Q2 FY2026 Ended Dec 31, 2025 | Feb 3, 2026 | During market hours | $15.20M | $-1.05 | – |
| Q1 FY2026 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | $13.90M | $-0.08 | – |
| Q4 FY2025 Ended Jun 30, 2025 | Sep 23, 2025 | During market hours | $15.10M | $-2.92 | – |
| Q3 FY2025 Ended Mar 31, 2025 | May 14, 2025 | During market hours | $18.50M | $0.21 | – |
| Q2 FY2025 Ended Dec 31, 2024 | Feb 12, 2025 | During market hours | $16.20M | $-0.26 | – |
| Q1 FY2025 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | $16.60M | $-0.15 | – |
| Q4 FY2024 Ended Jun 30, 2024 | Sep 26, 2024 | During market hours | $18.00M | $-0.82 | – |
| Q3 FY2024 Ended Mar 31, 2024 | May 15, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Dec 31, 2023 | Feb 14, 2024 | During market hours | – | – | – |
Press releases
Announcements Aytu Biopharma filed with the SEC
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
Results of operations · EX-99.1 to Form 8-K
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
Results of operations · EX-99.1 to Form 8-K
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
Results of operations · EX-99.1 to Form 8-K
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
Results of operations · EX-99.1 to Form 8-K
Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA™
Results of operations · EX-99.1 to Form 8-K
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA ™
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA ™ Opportunity and Commercialization Plan
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA™ (gepirone) Extended-Release Tablets in the United States
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results
Results of operations · EX-99.1 to Form 8-K
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results
Results of operations · EX-99.1 to Form 8-K
NOTICE OF PENDENCY OF DERIVATIVE ACTION,
Regulation FD disclosure · EX-99.1 to Form 8-K
Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results
Results of operations · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT® and Cotempla XR-ODT® in Canada
Regulation FD disclosure · EX-99.1 to Form 8-K
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
Results of operations · EX-99.1 to Form 8-K
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
Regulation FD disclosure · EX-99.1 to Form 8-K
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
Material agreement · New financial obligation · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results
Results of operations · EX-99.1 to Form 8-K
Aytu BioPharma Reports Record ADHD Revenue and Operating
Results of operations · EX-99.1 to Form 8-K
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Aytu BioPharma Announces Approval of the Cotempla XR-ODT® Manufacturing Site Transfer Prior Approval Supplement
Results of operations · EX-99.1 to Form 8-K
Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023
Results of operations · EX-99.1 to Form 8-K
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT® and Cotempla XR-ODT® in Israel and the Palestinian Authority
Regulation FD disclosure · EX-99.1 to Form 8-K
Aytu BioPharma Announces Submission of Cotempla XR-ODT®
Regulation FD disclosure · EX-99 to Form 8-K
BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New
Material agreement · Executive or director change · Other events · EX-99.1 to Form 8-K
Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aytu BioPharma Subleases a Portion of Its Manufacturing Facility
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Aytu BioPharma Announces Approval of Adzenys XR-ODT® Manufacturing Site Transfer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023
Results of operations · EX-99.1 to Form 8-K
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results
Regulation FD disclosure · EX-99.1 to Form 8-K
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Announces 1-for-20 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE
Other events · EX-99.1 to Form 8-K
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT ® Prescriptions Generated Since Inception of RxConnect
Regulation FD disclosure · EX-99.1 to Form 8-K
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso
Regulation FD disclosure · EX-99 to Form 8-K
Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023
Results of operations · EX-99 to Form 8-K
Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022
Regulation FD disclosure · EX-99.1 to Form 8-K